- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03925649
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI
July 2, 2021 updated by: Hope Biosciences
Individual Patient Expanded Access IND (Investigational New Drug) of Autologous HB-adMSCs for the Treatment of Spinal Cord Injury
This study is expanded access to an Investigational New Drug (IND) for an individual patient with spinal cord injury (SCI) at cervical spine 5-6 (C 5-6) designed to provide access to autologous adipose-derived mesenchymal stem cells (HB-adMSCs)
Study Overview
Status
No longer available
Conditions
Intervention / Treatment
Detailed Description
This is an expanded access single-dose study with the primary goal of treatment submitted at the request of an individual patient with complete C5-6 spinal cord injury (SCI) resulting in quadriplegia who does not qualify for any current clinical trials and for whom there are no other FDA approved fully restorative treatments.
The overall objective of this study is to evaluate patient's response, adverse events and serious adverse events (AE/SAEs), and cell expansion characteristics of a single intravenous (IV) infusion of autologous adipose-derived mesenchymal stem cells (HB-adMSCs) in a subject with complete SCI resulting in quadriplegia.
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
- Intermediate-size Population
- Treatment IND/Protocol
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Cognitively intact, capable of giving informed consent
- Clinical diagnosis of a non-penetrating traumatic SCI
- Asia Impairment Scale grade of A, B, or C
Exclusion Criteria:
Prior history of:
- Brain injury
- Recent or ongoing infection
- Clinically significant cardiovascular, lung, renal, hepatic or endocrine disease,
- Neurodegenerative disorders
- Cancer
- Immunosuppression as defined by WBC<3,000 cells/ml at baseline screening,
- HIV+
- Chemical or ETOH dependency
- Having a contraindication to MRI scans
- Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration
- Participation in other interventional research studies
- Unwillingness to return for follow-up visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 16, 2019
First Submitted That Met QC Criteria
April 18, 2019
First Posted (Actual)
April 24, 2019
Study Record Updates
Last Update Posted (Actual)
July 6, 2021
Last Update Submitted That Met QC Criteria
July 2, 2021
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HBSCI01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injury at C5-C7 Level
-
Kevin KilgoreNational Institute of Neurological Disorders and Stroke (NINDS); Case Western... and other collaboratorsRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury Cervical | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C5-C7 Level With Incomplete LesionUnited States
-
Azienda Ospedaliero, Universitaria PisanaCompletedSpinal Cord Injury at C5-C7 Level
-
MetroHealth Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Case Western...RecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury CervicalUnited States
-
S.Biomedics Co., Ltd.Yonsei University; Linical Co., Ltd.RecruitingSpinal Cord Injury, Acute | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C4 Level With Complete LesionKorea, Republic of
-
Bronx VA Medical CenterNew York State Department of HealthCompletedSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Tetraplegia/TetraparesisUnited States
-
University of ManitobaRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Paraplegia, Spinal | Paraplegia, IncompleteCanada
-
The Alfred E. Mann Foundation for Scientific ResearchWalter Reed Army Medical CenterTerminatedSpinal Cord Injury at C5-C7 Level With Incomplete LesionUnited States
-
University of British ColumbiaUniversity of Toronto; Queen's University; Dalhousie University; Wings for LifeRecruitingUpper Extremity Dysfunction | Cervical Spinal Cord Injury | Spinal Cord Injury | Spinal Cord Injury at C5-C7 Level | SCI - Spinal Cord Injury | Upper Extremity Paralysis | Tetraplegia | Upper Extremity ParesisCanada
-
Nicholls Spinal Injury FoundationUniversity College, London; Poznan University of Medical Sciences; Wroclaw Medical... and other collaboratorsRecruitingSpinal Cord Injury at C5-Th10 Level With Complete Lesion | Spinal Cord TransectionPoland
-
Ohio State UniversityCompletedSpinal Cord Injury at C4-C6 LevelUnited States
Clinical Trials on HB-adMSCs
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonActive, not recruiting
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableParkinson DiseaseUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availablePost COVID-19 SyndromeUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableAmyotrophic Lateral SclerosisUnited States
-
Hope Biosciences Stem Cell Research FoundationNo longer available
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableCongenital Muscular Dystrophy Due to Lamin A/C MutationUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesCompleted
-
Hope BiosciencesCompletedRheumatoid ArthritisUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesWithdrawn
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer available